Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

CAS：105816-04-4
中文别名：氘代那格列奈-d5;N-(反式-4-异丙基环己基甲酰)-D-苯丙氨酸;
英文别名：DJN 608;Glinate;STARLIX;Fastic-d5;Natelide;A-4166;ay4166;N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine;Nateglinide;Starsis;Starlix DS;Fastic;
分子式：C19H27NO3
分子量：317.423
精确质量：317.199
Psa：66.4
Logp：3.6518

UNII：41X3PWK4O2

外观与性状：白色结晶粉末
密度：1.104 g/cm3
沸点：527.6ºC at 760 mmHg
熔点：137-141ºC
闪点：272.9ºC
折射率：1.536
储存条件：Room temp
蒸汽压：0mmHg at 25°C

RTECS号：SQ7318950
安全说明：S24/25; S36
危险类别码：R22
海关编码：2924299090
危险品标志：Xn

用途
降糖药物。